Stapley Marc 4

What Happened
Marc Stapley, CEO of Veracyte, was granted 92,099 restricted stock units (RSUs) on March 6, 2026. The Form 4 shows an acquisition at $0.00 per share (code A — award/grant). This was a compensation award, not an open‑market purchase or sale.

Key Details

• Transaction date: March 6, 2026; Filed: March 10, 2026 (Form 4) — filing appears timely (within required reporting window).
• Security and amount: 92,099 restricted stock units (RSUs) acquired at $0.00.
• Shares owned after transaction: Not specified in the filing.
• Vesting/footnote: RSUs vest 25% on March 2, 2027 and then 1/16 of the total per quarter thereafter, subject to continued employment (footnote F1).
• Transaction code: A = Award/Grant. No 10b5‑1 plan, tax‑withholding, or sale noted in this filing.

Context
RSU grants are a routine form of executive compensation and do not reflect an open‑market purchase or sale. The economic value to the insider depends on Veracyte’s stock price at each vesting date; vesting is time‑based and contingent on continued employment. Purchases or sales by insiders are often more indicative of personal conviction, while grants are typically part of compensation packages.